Therefore, the use of osimertinib is recommended as first-line chemotherapy for EGFR-mutated NSCLC as well as other EGFR-TKIs with or without anti-Vascular Endothelial Growth Factor (VEGF) antibodies [9]. This evidence concerns the gene VEGFA and non-small cell lung carcinoma.